Mikhail Blagosklonny
| Mikhail Blagosklonny | |
|---|---|
| Fields | Anti-Aging Medicine, Cancer |
| Institutions | Roswell Park Cancer Institute |
| Education | MD, PhD |
| Alma mater | First Pavlov State Medical University of St. Peterburg |
Mikhail Blagosklonny is a leading scientist researching in anti-aging medicine and cancer. In 2009, he was appointed Professor of Oncology at the Roswell Park Cancer Institute in New York.[1] His scientific work has received almost 20,000 citations since 1987 with over 10,000 citations since 2009.[2]
Education
Blagosklonny earned both his M.D. (Medical Doctorate) in internal medicine and his PhD in experimental medicine & cardiology from the leading Russian medical university the First Pavlov State Medical University of St. Peterburg.[1]
Career
Blagosklonny was appointed Associate Professor of Medicine at New York Medical College, Valhalla, NY in 2002 before being headhunted for the position of Senior Scientist at Ordway Research Institute, Albany, New York. Blagosklonny held this position until 2009 when he was appointed Professor of Oncology at Roswell Park Cancer Institute.
Blogosklonny's research interests include methods to suppress the aging process in order to prevent age-related diseases including cancer, the underlying mechanisms of aging (biogerontology), anti-aging drugs and targeted cancer therapies that protect normal cells from damage. He is renown for his hypothesis that biological aging is caused by developmental pathways, particularly TOR, continuing unhindered past maturity in a hyper-functioning state [3]
Editorial Positions
Editor-in-Chief & Co-Founding editor: Aging;[4] the second highest ranked journal in the field of aging research [5]
Editor-in-Chief & Founding editor: Cell Cycle.[6]
Editor-in-Chief: Oncotarget;[7]
Associate Editor: PLOS ONE (the 3rd most cited scientific journal in the world as of 2000-2012[8]); Cancer Biology & Therapy; Autophagy; Cancer Research; Cell Death and Differentiation; International Journal of Cancer; The American Journal of Pathology.[1]
Founding member: 700forscience;[9] a group of commercialization experts helping to create a grassroots support system, for innovative biotechnology projects.[10]
Selected Recent & Seminal Academic Papers
- Oncotarget. 2012 Dec;3(12):1711-24. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Blagosklonny MV.
- Cell Cycle. 2010 Dec 15;9(24):4788-94. Epub 2010 Dec 15. Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. Blagosklonny MV.
- Cell Cycle. 2010 Aug 15;9(16):3151-6. doi: 10.4161/cc.9.16.13120. Epub 2010 Aug 20. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Blagosklonny MV.
- Aging 2012 Dec; 4(12):861-77. Answering the ultimate question "What is the Proximal Cause of Aging? 2007 Mikhail V. Blagosklonny
- Cell Cycle 15 December 2007; 6:24, 2997-3003; Paradoxes of Aging 2007 Mikhail V. Blagosklonny
- Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G (January 2009). "Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009". Cell Death Differ. 16 (1): 3–11.doi:10.1038/cdd.2008.150. PMC 2744427. PMID 18846107.
- Blagosklonny, Mikhail V.; Pardee, Arthur B. (2001). "The Restriction Point of the Cell Cycle". In Blagosklonny, Mikhail V. Cell Cycle Checkpoints and Cancer. Austin: Landes Bioscience. pp. 52–?. ISBN 978-1-58706-067-0.
- Stabilization of wild-type p53 by hypoxia-inducible factor 1α WG An, M Kanekal, MC Simon, E Maltepe, MV Blagosklonny, LM Neckers Nature 392 (6674), 405-408
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 L Galluzzi, I Vitale, JM Abrams, ES Alnemri, EH Baehrecke, ...Cell Death & Differentiation 19 (1), 107-120
- p53 is associated with cellular microtubules and is transported to the nucleus by dynein P Giannakakou, DL Sackett, Y Ward, KR Webster, MV Blagosklonny, ... Nature cell biology 2 (10), 709-717